NASDAQ$CMPS

COMPASS Pathways plc · Q1 2025 earnings

Q1 2025 earnings · · Before market open · Investor relations

Briefing

Compass Pathways reported Q1 2025, net loss of $17.9M, diluted EPS of $-0.20.

For Q1 2025, Compass Pathways reported a net loss of $17.9M, diluted EPS was $-0.20. Management discusses operating trends, capital, and sector risks in the quarterly filing.

  • Net loss $17.9M.
  • Diluted EPS $-0.20.
  • Compass Pathways highlights liquidity, execution, and sector-specific risks in MD&A.

Headline financials

Total Revenue

$0.00

Previous: $0.00
EPS (adj)

-$0.20

Previous: -$0.55+63.6%
Weighted Average Ordinary Shares Outstanding (Basic)

89.2M

No prior period
Weighted Average Ordinary Shares Outstanding (Diluted)

98.6M

No prior period
Net Loss Per Share (Diluted)

-$0.24

No prior period
Research and Development Expenses

$30.9M

No prior period
General and Administrative Expenses

$18.7M

No prior period
Fair Value Change of Warrant Liabilities

$19.5M

No prior period
Benefit from R&D Tax Credit

$8.45M

No prior period
Interest Income

$2.39M

No prior period
Foreign Exchange Gains (Losses)

$2.13M

No prior period
Interest Expense

-$1.12M

No prior period
Other Income

$803K

No prior period
Net Cash Used in Operating Activities

-$45.7M

No prior period
Net Cash Provided by Financing Activities

$140M

No prior period
Net Income

-$17.9M

Previous: -$35.2M+49.2%
Operating Income

-$49.6M

Previous: -$38.6M-28.7%

Revenue & EPS history

COMPASS · Revenue · Quarterly

$0

Q1 2025

Forward guidance

Clinical and pre-commercial biotech filers emphasize trial milestones, regulatory paths, and cash runway.

Tailwinds

  • Pipeline progress and partnership optionality.
  • Cash funding operations into catalysts.
  • Regulatory designations where applicable.

Headwinds

  • Trial failure or delay risk.
  • Dilution from equity raises.
  • Limited product revenue for most programs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2025

Historical avgQ1 2025

-0.7%

Avg return

Earnings day

+0.6%

Avg return

5 days after

+4.1%

Avg return

30 days after

32%

6 / 19 earnings

Positive

+25.1%

Q2 2022

Best reaction

-23.3%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-5.9%+12.7%+29.1%
Q3 2025-0.5%+4.7%-12.3%
Q1 2025+0.5%+4.3%+28.3%
Q4 2024+5.9%+4.1%-20.5%
Q3 2024-23.3%-27.0%-25.8%
Q1 2024+0.0%-4.9%-18.7%
Q4 2023-7.2%-12.1%-32.7%
Q3 2023+10.9%+4.7%+5.5%
Q2 2023-4.7%-8.8%+4.2%
Q1 2023-4.1%-2.3%-8.7%
Q4 2022-3.4%+0.8%+23.3%
Q3 2022+2.0%-3.9%+14.4%
Q2 2022+25.1%+18.1%+4.6%
Q1 2022-8.2%+3.7%+33.0%
Q4 2021+8.1%+15.5%-1.1%
Q2 2021-5.8%-8.1%+5.4%
Q4 2020-1.2%+4.5%-5.9%
Q4 2019-1.2%+4.5%-5.9%
Q3 2020-0.2%+1.4%+61.6%
Q1 2020
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro